Asahi Kasei to Supply 1 MW-Class Alkaline-Water Electrolyzer to Hydrogen Project in Finland
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730330883/en/
Having launched its chlor-alkali electrolysis business in 1975, Asahi Kasei leveraged its technology and expertise to develop water electrolysis systems for hydrogen production. In 2020, the company installed its large-scale 10 MW-class Aqualyzer™ electrolyzer at the Fukushima Hydrogen Energy Research Field (FH2R) in Namie, Futaba, Fukushima, Japan. Following the success of the FH2R project, Aqualyzer™-C 3 was added to its portfolio in 2024 as a small-scale, containerized system in the range of 1 to 7.5 MW. This allows Asahi Kasei to meet emerging diversified needs of customers across the entire hydrogen market, with significant growth expected.
Cefmof is a foundation that accelerates the development of sustainable mobility and urban planning by harnessing green hydrogen — particularly in ways that are tangible and visible in people's everyday lives. It was established by the City of Jyväskylä, TOYOTA GAZOO Racing World Rally Team, and the Toyota Mobility Foundation. The foundation supports projects such as hydrogen-powered transport and related infrastructure. Cefmof plans to use fuel cell vehicles and hydrogen buses, serving as a case model for the potential of hydrogen utilization in cold climates and the mobility industry.
Easy scalability to meet growing demand
For the reliable and efficient supply of hydrogen, Cefmof chose Asahi Kasei's container-type Aqualyzer™-C 3 with a capacity of 1 MW. The installation in Jyväskylä is expected to commence towards the end of 2025, aiming for full-scale operation in the first half of 2026. The system will be able to produce enough hydrogen in an hour to refill approximately three fuel cell vehicles (FCVs).
The containerized modular design allows for gradual expansion of production capacity through the connection of additional units, allowing for flexibility in meeting future increases in hydrogen demand.
'With this project, our hydrogen-related business has moved fully into the commercialization phase,' noted Kenji Takeda, Executive Officer of Asahi Kasei responsible for Business Development of its Green Solution Project. 'We will work with our partners to demonstrate the reliability of our alkaline water electrolysis system through installation in extreme cold-climate environments and contribute to the decarbonization of the Central Finland region. We are proud to be a one-stop supplier providing support from installation to hydrogen production operations.'
'This project will be a key part of the emerging green hydrogen ecosystem in Central Finland and highlights Cefmof's long-term commitment to building a carbon neutral future in the region,' says Haruka Arai, Executive Director of Cefmof. 'This development supports the practical realisation of a functioning hydrogen refueling infrastructure in Jyväskylä.'
As part of its medium-term management plan, Asahi Kasei positions its hydrogen-related business as an area of Growth Potential and is making investments toward full-scale commercialization. By leveraging intangible assets such as the customer base and technologies that have been cultivated through its existing chlor-alkali business using ion-exchange membranes, the company is steadily advancing initiatives, including collaborations with a variety of partners.
About Asahi Kasei
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 50,000 employees worldwide, the company contributes to sustainable society by providing solutions to the world's challenges through its three business sectors of Healthcare, Homes, and Material. For more information, visit https://www.asahi-kasei.com/.
https://www.asahi-kasei.com/sustainability/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
5 hours ago
- Globe and Mail
Why Novo Nordisk Flew Almost 3% Higher on Friday
Key Points The company's leading product looked more attractive following price hikes by a competitor. Eli Lilly's Zepbound will become more expensive in the U.K. and likely throughout Europe subsequently. 10 stocks we like better than Novo Nordisk › An archrival's pricing move was seen as beneficial for Novo Nordisk (NYSE: NVO) on Friday. As investors disseminated news of a dramatic increase in the cost of a product competing with the company's star drug, Wegovy, they pushed the Danish pharmaceutical company's share price up. It closed the day almost 3% higher during a session when the S&P 500 index ended up slumping by 0.3%. A rival's hikes The previous day, U.S. healthcare giant Eli Lilly announced that it was raising the prices of Zepbound -- a GLP-1 obesity drug that directly competes with Wegovy -- in the U.K. In doing so, the company indicated that it will follow suit in other European markets. The move follows a Trump administration push to reduce drug prices in America (or, at least, effectively level them across the world). In late July, the president sent letters to the CEOs of top U.S. drug companies, stating that they had until Sept. 29 to reduce the costs of certain medications. Failure to do so, the president wrote somewhat vaguely, would see the federal government "deploy every tool in our arsenal to protect American families." Although Novo Nordisk also received one of these letters -- there were 17 in all -- the company hasn't given any concrete indication that it intends to make adjustments similar to Eli Lilly's. Customer rebellion brewing? For the moment, then, Novo Nordisk enjoys a bit of an advantage, as there is inevitably customer backlash (and often defection to rival products) when a company hikes prices. We've yet to see how Trump's initiative will fully play out, however. So, personally, I don't think any investor should base their Novo Nordisk stance on the Eli Lilly development. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
CTV News
9 hours ago
- CTV News
Putin does not want to give Trump ‘a reason to go home unhappy': Townsend
Watch Former Deputy Assistant Secretary of Defense for European & NATO Policy Jim Townsend on why U.S. tariffs on Russian gas could lead to ceasefire.
Globe and Mail
10 hours ago
- Globe and Mail
Smith & Nephew (SN) Receives a Hold from Stifel Nicolaus
Stifel Nicolaus analyst Dylan Van Haaften maintained a Hold rating on Smith & Nephew today and set a price target of £14.15. The company's shares closed today at p1,353.00. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Van Haaften covers the Healthcare sector, focusing on stocks such as Merck KGaA, Smith & Nephew, and Sartorius. According to TipRanks, Van Haaften has an average return of -5.5% and a 32.65% success rate on recommended stocks. In addition to Stifel Nicolaus, Smith & Nephew also received a Hold from Berenberg Bank's Sam England in a report issued on August 11. However, yesterday, Bank of America Securities reiterated a Buy rating on Smith & Nephew (LSE: SN). SN market cap is currently £11.76B and has a P/E ratio of 30.99. Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SN in relation to earlier this year.
